<DOC>
	<DOCNO>NCT00678392</DOCNO>
	<brief_summary>The study design demonstrate axitinib ( AG-013736 ) superior sorafenib delay tumor progression patient metastatic renal cell cancer failure one first line regimen .</brief_summary>
	<brief_title>Axitinib ( AG 013736 ) As Second Line Therapy For Metastatic Renal Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Histologically cytologically confirm renal cell cancer component clear cell subtype , metastasis Evidence measurable disease Must fail one prior systemic firstline regimen metastatic renal cell cancer Prior treatment metastatic renal cell cancer one systemic first line therapy Major surgery less 4 week radiation le 2 week start study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Axitinib Second Line Treatment Patients With Metastatic Renal Cell Cancer</keyword>
</DOC>